Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double-blind, randomized, placebo- controlled trial

Infectious Diseases in Clinical Practice

Volumn 9, Issue 4, 2000, Pages 169-175

  Ables, Adrienne Z ^a,d   Blumer, Nancy A ^b   Valainis, Gregory T ^a   Godenick, Mark T ^a   Kajdasz, Daniel K ^c   Palesch, Yuko Y ^c  

^a Gibbs Cancer Center and Research Institute   (United States)

^b GREENVILLE HOSPITAL SYSTEM   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d Center for Family Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFICACY; FEMALE; HOSPITALIZATION; HUMAN; INCIDENCE; INJURY; INTESTINE; MAJOR CLINICAL STUDY; MALE; MORTALITY; POSTOPERATIVE INFECTION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0034095157     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-200009040-00006     Document Type: Article

References (37)

1. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 1993;167:1247-51.
2. Haley RW, Schaberg DR, Van Allmen SD, et al. Estimating the extra charges and prolongation of hospitalization due to nosocomial infections: a comparison of methods. J Infect Dis 1980;141:248-57.
3. Wey SB, Mori M, Pfaller MA, et al. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1988;148:2642-5.
4. Gaines JD, Remington JS. Disseminated candidiasis in the surgical patient. Surgery 1972;72:730-6.
5. Dennis DL, Peterson CG, Fletcher WS. Candida septicemia in the severely traumatized patient. J Trauma 1968;8:177-85.
6. Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in medical intensive care units in the United States. Crit Care Med 1999;27:887-92.
7. Klein JJ, Watanakunakorn C. Hospital-acquired fungemia: its natural course and clinical significance. Am J Med 1979;67:51-8.
8. Marsh PK, Tally FP, Kellum J, et al. Candida infections in surgical patients. Ann Surg 1983;198:42-7.
9. Meunier-Carpentier I, Kiehn TE, Armstrong D. Fungemia in the immunocompromised host: changing patterns, antigenemia, high mortality. Am J Med 1981;71:363-70.
10. Curry CR, Quie PG. Fungal septicemia in patients receiving parenteral hyperalimentation. N Engl J Med 1971; 285:1221-5.
11. Wey SB, Mori M, Pfaller MA, et al. Risk factors for hospital-acquired candidemia: a matched case-control study. Arch Intern Med 1989;149:2349-53.
12. Crislip MA, Edwards JE. Candidiasis. Infect Dis Clin North Am 1989;3:103-33.
13. Frazer VJ, Jones M, Dunkel J, et al. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992;15:414-21.
14. Komshian SV, Uwaydah AK, Sobel JD, et al. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989;11:379-90.
15. Weinstein MP, Murphy JR, Reller LB, et al. The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. II. Clinical observations, with special reference to factors influencing prognosis. Rev Infect Dis 1983; 5:54-70.
16. Dyess DL, Ganison RN, Fry DE. Candida sepsis: implications of polymicrobial bloodborne infection. Arch Surg 1985;120:345-8.
17. Horn R, Wong B, Kiehn TE, et al. Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis 1985;7:646-55.
18. Bennett JE. Antimicrobial agents: antifungal agents. In: Gilman AG, Rall TW, Nies AS, Taylor P, editors. The pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press; 1990. p. 1165-81.
19. DeWit S, Weerts D, Goossens H, et al. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet 1989;1:746-8.
20. Laine L, Dretler RH, Conteas CN, et al. Fluconazole compared with ketoconazole for the treatment of candida esophagitis in AIDS. Ann Intern Med 1992;117:655-62.
21. Brammer KW, Feczko JM. Single-dose oral fluconazole in the treatment of vaginal candidiasis. Ann N Y Acad Sci 1988;544:561-3.
22. Stein GE, Christensen S, Mummaw N. Comparative study of fluconazole and clotrimazole in the treatment of vulvovaginal candidiasis. DICP 1991;25:582-5.
23. Robinson PA, Knirsch AK, Joseph JA. Fluconazole for life-threatening infections in patients who cannot be treated with conventional antifungal agents. Rev Infect Dis 1990;12(3 Suppl):S349-S363.
24. Van't Wout JW, Mattie H, van Furth R. A prospective study of the efficacy of fluconazole (UK-49,858) against deep-seated fungal infections. J Antimicrob Chemother 1988;21:665-72.
25. Corbella X, Sirvant JM, Carratala J. Fluconazole treatment without cathter removal in Candida albicans peritonitis complicating peritoneal dialysis [letter]. Am J Med 1991;90:277.
26. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51.
27. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
28. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644-55.
29. Safran DB, Dawson E. The effect of empiric and prophylactic treatment with fluconazole on yeast isolates in a surgical trauma intensive care unit. Arch Surg 1997;132:1184-9.
30. Gleason TG, May AK, Caparelli D, et al. Emerging evidence of selection of fluconazole-tolerant fungi in surgical intensive care units. Arch Surg 1997;132:1197-202.
31. Munshi I, Sleeman D, Parra-Davita E, et al. Fluconazole prophylaxis in critically ill trauma intensive care unit patients. Poster presented at SCCM's 27th Educational and Scientific Symposium; 1998 Feb 4-8; San Antonio, TX.
32. Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intraabdominal candidiasis in high-risk surgical patients. Crit Care Med 1999;27:1066-72.
33. Vinsant GO, Todd J, Fallon W. Reduction of candida infections in the high-risk trauma patient. Poster presented at the American College of Surgeons Clinical Congress; 1993 Oct 11-14; San Francisco, CA.
34. Nicolau DP, Crowe H, Nightingale CH, et al. Bioavailability of fluconazole administered via a feeding tube in intensive care unit patients. J Antimicrob Chemother 1995;36:395-401.
35. Rosemurgy AS, Markowsky S, Goode SE, et al. Bioavailability of fluconazole in surgical intensive care unit patients: a study comparing routes of administration. J Trauma 1995;39:445-7.
36. Wingard JR, Merz WG, Rinaldi, MG, et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991;325:1274-7.
37. Wingard JR, Merz WG, Rinaldi, MG, et al. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993;37:1847-9.